4 employees
OrganoTherapeutics use mini-brains for the discovery and development of effective drug candidates targeting Parkinson’s disease.
2019
OrganoTherapeutics raised undisclosed on July 26, 2023
Investors: KHANU Management GmbH
OrganoTherapeutics raised undisclosed on October 21, 2020
Investors: Creative Destruction Lab